This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks That Make Prime Acquisition Targets

NEW YORK ( Stockpickr) -- It doesn't take a lot of vision to predict that the medical device industry will see a lot of acquisitions in 2012. After all, it happens every year.

The industry's biggest players, such as Medtronic (MDT), Boston Scientific (BSX) and Roche Holdings, struggle to find ways to organically boost revenue. So they do the next best thing: Buy their way into growth. These deal-makers typically seek to bring in more products for their sales forces to pitch to customers, or they look to expand their technological knowhow by incorporating other firm's products and R&D efforts into their own.

>>5 Rocket Stocks Ready to Blast Off

Case in point: Roche Holdings recent efforts to acquire Illumina (ILMN). Roche wants to quickly establish a strong presence in the field of DNA analysis, and Illumina, the industry leader, provides just such an entry into the space.

Here are five other medical device firms that could hold great appeal for the industry's larger players.


Nuvasive (NUVA - Get Report) has quickly gained traction in the field of minimally invasive spinal surgery. Sales grew steadily throughout the last decade, and management poured the company's cash flow back into R&D and an expanded salesforce.

Trouble is, the shaky health care spending environment has led to temporary reimbursement challenges from insurers. As a result, Nuvasive's sales growth is slowing. 25% top-line growth is now in the teens and could hit just 10% in 2013.

Yet over the long haul, this should remain a steady grower. Nuvasive's technology yields shorter hospital stays and reduced recurrences of back pain, which saves the health care system money in the long-term.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ANGO $12.29 -1.76%
BSDM $1.12 -10.40%
DSCI $3.20 -4.19%
NUVA $52.60 -0.08%
PACB $8.61 1.65%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs